The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

891728891508890149a558a0d4-9d99-4c70-a4ff-a328919a3c82a2245228-7537-48b8-a80f-237ba9cb72f2363d8990-e2cf-4c03-9e5b-bef154f7db81ARGS_News_2016_5_12_General_Releases.pdfARGS_News_2016_5_11_General_Releases.pdfARGS_News_2016_5_5_General_Releases.pdf2329912625109761232016-5-12T16:5:0-4:02016-5-11T16:5:0-4:02016-5-5T8:0:0-4:0970786970558969370General ReleasesGeneral ReleasesGeneral ReleasesSpecial advisor and former chief operating officer Dr. Fred Miesowicz to join panel discussion on cell therapy manufacturingArgos Therapeutics Reports First Quarter 2016 Financial Results and Operational HighlightsArgos Therapeutics to Participate in World Stem Cells and Regenerative Medicine CongressArgos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016134134134201620162016No Error0

Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights
Read more

Argos Therapeutics to Participate in World Stem Cells and Regenerative Medicine Congress
Read more

Argos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC